钆塞酸二钠对动脉期呼吸波形的影响:基于定量快速傅里叶变换分析
研究纳入107例肝脏MRI受试者,分别使用钆塞酸二钠(40例)或钆贝葡胺(67例),用快速傅里叶变换分析呼吸波形。钆塞酸二钠组动脉期呼吸波形偏差更大且更不可预测(D2 438±381 vs 167±167,p<0.001),常伴一过性呼吸急促。
要点
- 钆塞酸二钠组动脉期呼吸波形偏差D2为438±381,大于钆贝葡胺组的167±167(p<0.001)。
- 钆塞酸二钠组动脉期异常呼吸波形发生率48%(19/40),高于钆贝葡胺组的1%(1/67)(p<0.001)。
- 动脉期异常呼吸波峰通常伴一过性呼吸急促,钆塞酸二钠组动脉期平均最大呼吸频率27次/分(范围11-40次/分)。
核心结论
- 固定剂量钆塞酸二钠(10 mL,与10 mL生理盐水1:1稀释,注射速率2 mL/s)会一过性降低动脉期屏气能力,并伴短暂一过性呼吸急促。
研究设计与样本
- 2013至2015年纳入107例肝脏MRI受试者,钆塞酸二钠组40例(10 mL与生理盐水1:1稀释,注射速率2 mL/s),钆贝葡胺组67例(0.2 mL/kg,最大20 mL,注射速率2 mL/s)。
诊断标准与关键数值
- D1为同一受试者两个对照期(平扫期与晚期动态期)的平均均方根差,钆塞酸二钠组232±203 vs 钆贝葡胺组201±230(p=0.48)。
- D2为动脉期相对于对照记录均值的均方根偏差,钆塞酸二钠组438±381 vs 钆贝葡胺组167±167(p<0.001)。
- 受试者水平动脉期异常呼吸波形发生率:钆塞酸二钠组48%(19/40)vs 钆贝葡胺组1%(1/67)(p<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to investigate the effect of gadoxetate disodium administration on arterial phase respiratory waveforms.
SUBJECTS AND METHODS: From 2013 to 2015, 107 subjects undergoing liver MRI with either gadoxetate disodium (10 mL diluted 1:1 with saline; injection rate, 2 mL/s; n = 40) or gadobenate dimeglumine (0.2 mL/kg; maximum, 20 mL; injection rate, 2 mL/s; n = 67) were enrolled. Respiratory waveforms obtained during unenhanced and dynamic contrast-enhanced phases were filtered by a physicist, who was blinded to contrast agent and imaging phase, to eliminate electronic and cardiac noise using fast Fourier transformation. The average root-mean-square difference of two intrasubject control phases (unenhanced and late dynamic) was termed D1, and the root-mean-square deviation of the arterial phase referent to the control record mean was termed D2. D1, D2, and their difference were compared across agents with the Mann-Whitney U test. Bland-Altman plots were generated for D1 and D2 values.
RESULTS: D1 values were similar for both agents (mean [± SD], 232 ± 203 for gadoxetate vs 201 ± 230 for gadobenate; p = 0.48), indicating similar intercohort baseline breath-holding capability. D2 was greater and more variable for the gadoxetate cohort (438 ± 381) than for the gadobenate cohort (167 ± 167; p < 0.001), indicating larger and more unpredictable respiratory waveform deviations isolated to the arterial phase (subject-level rate, 48% [19/40] for gadoxetate vs 1% [1/67] for gadobenate; p < 0.001). Aberrant respiratory waveform peaks in the arterial phase were usually associated with transient tachypnea (mean maximum arterial phase respiratory rate for the gadoxetate cohort, 27 breaths/min; range, 11-40 breaths/min).
CONCLUSION: Fixed-dose gadoxetate disodium (10 mL; 1:1 dilution with 10 mL of saline; injection rate, 2 mL/s) transiently reduces breath-holding capacity during the arterial phase and is accompanied by brief transient tachypnea.
引用
- Davenport MS, Malyarenko DI, Pang Y, et al. Effect of Gadoxetate Disodium on Arterial Phase Respiratory Waveforms Using a Quantitative Fast Fourier Transformation-Based Analysis. AJR Am J Roentgenol. 2016. PMID: 27929673. doi:10.2214/AJR.16.16860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。